Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kissei's MRs Provide Drug Safety Data on the Spot
April 9, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 9, 2007
- St. Gallen Consensus Most Commonly Referred to by Japanese Oncologists in Breast Cancer Treatment: Seminar
April 2, 2007
- Personalized Treatment with Irinotecan Starts
April 2, 2007
- Kissei Aims at 20% Share for Urief in FY2007
April 2, 2007
- Risk of Death Reduced in People Examined for Colorectal Cancer
April 2, 2007
- GSK Enhances Oncology Marketing Forces
April 2, 2007
- Risk of Localized Prostate Cancer Reduced by Soy Products
April 2, 2007
- BUSINESS NEWS IN BRIEF
April 2, 2007
- Entecavir Is 1st-Choice Drug for Chronic Hepatitis B: Dr Kumada
April 2, 2007
- Korosho Orders Chugai to Issue "Dear-Doctor Letter" on Tamiflu
April 2, 2007
- NEW PRODUCTS
April 2, 2007
- Relenza in Short Supply
April 2, 2007
- Eli Lilly to Enhance Presence in GP Market: Mr Crenshaw
April 2, 2007
- Council to Propose Strategies to Enhance Global Competitiveness
April 2, 2007
- Eisai Embarks on Antibody Pharmaceuticals Business by Acquiring Morphotek
April 2, 2007
- REGULATORY NEWS IN BRIEF
April 2, 2007
- Suzuken to Place Top Priority on Customer Satisfaction, Promote M&As: New President Ota
April 2, 2007
- JMA Symposium on Stimulation of Clinical Trials
April 2, 2007
- Market for Ethical Drugs in Japan Fell 0.6% in 2006: IMS
April 2, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…